NIAID Emerging and Re-emerging Infectious Diseases NIAID Bioinformatics Resource Centers NIAID Structural Genomic Centers Center for Structural Genomics of Infectious Disease
Seattle Structural Genomics Center for Infectious Disease

MyabA.01530.a: Possible enoyl-CoA hydratase

Target Characteristics

from organism: Mycobacterium abscessus ATCC 19977 / DSM 44196
most recent status: soluble
center reference id: MyabA.01530.a
is community request: False
associated disease: Skin abscess
NIH risk group: 2
is select agent: False
NIH priority
pathogens category:
IIIC

Ordering Clones & Proteins

If there are materials available for this target, they will be listed below. Materials can be ordered from SSGCID using the button in the "order material" column. Clicking the button will add the material to a virtual cart. You may order multiple materials at a time at no cost to you, as this contract is funded by NIAID. When you are ready to place your order, click the "Place Order" link which will appear in the top right corner of the page after you place your first item in your cart.

External Resources

Resource Reference ID
OrthoMCL: OG5_169926
PATRIC ID: fig|36809.5.peg.4242
RefSeq: YP_001704891.1
UniProt: B1MIL6

Enzyme & Pathway Information

Pathway Pathway ID EC Number
fatty acid beta-oxidation I FAO-PWY 4.2.1.17
L-isoleucine degradation I ILEUDEG-PWY 4.2.1.17
oleate beta-oxidation PWY0-1337 4.2.1.17
phenylacetate degradation I (aerobic) PWY0-321 4.2.1.17
benzoyl-CoA degradation I (aerobic) PWY-1361 4.2.1.17
fermentation to 2-methylbutanoate PWY-5109 4.2.1.17
fatty acid beta-oxidation II (peroxisome) PWY-5136 4.2.1.17
unsaturated, even numbered fatty acid beta-oxidation PWY-5138 4.2.1.17
superpathway of glyoxylate cycle and fatty acid degradation PWY-561 4.2.1.17
superpathway of phenylethylamine degradation PWY-6071 4.2.1.17
4-hydroxybenzoate biosynthesis III (plants) PWY-6435 4.2.1.17
fatty acid beta-oxidation VI (peroxisome) PWY66-391 4.2.1.17
pyruvate fermentation to hexanol (engineered) PWY-6863 4.2.1.17
superpathway of cholesterol degradation I (cholesterol oxidase) PWY-6928 4.2.1.17
superpathway of testosterone and androsterone degradation PWY-6937 4.2.1.17
androstenedione degradation PWY-6944 4.2.1.17
superpathway of cholesterol degradation II (cholesterol dehydrogenase) PWY-6947 4.2.1.17
methyl ketone biosynthesis (engineered) PWY-7007 4.2.1.17
4-coumarate degradation (anaerobic) PWY-7046 4.2.1.17
fatty acid salvage PWY-7094 4.2.1.17
jasmonic acid biosynthesis PWY-735 4.2.1.17
docosahexaenoate biosynthesis III (6-desaturase, mammals) PWY-7606 4.2.1.17
(8E,10E)-dodeca-8,10-dienol biosynthesis PWY-7654 4.2.1.17
Spodoptera littoralis pheromone biosynthesis PWY-7656 4.2.1.17
(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate biosynthesis (6-desaturase) PWY-7726 4.2.1.17
toluene degradation to benzoyl-CoA (anaerobic) PWY-81 4.2.1.17
L-valine degradation I VALDEG-PWY 4.2.1.17

Sequences

These sequences are the native gene sequence; sequences of constructs derived from these sequences may differ due to codon optimization or other protocols. To find the specific sequence of any material you may have ordered, click on the "more" button next to the name of that material.
AA Sequence
MTEADALRAS GSSHTVTEQD APHALVELRD HVLIVTMNRP HARNALSGEM LEIMTQAWDR VDNDPEVRVC ILTGAGGYFC AGADLKAMNK RAPGDQFSDG SYDPSVIPGL LKGRRLTKPL IAAVEGPAIA GGTEILQATD IRVAGESAKF GVSEVKWSLY PMGGSAVRLP RQIPYTVACD ILLTGRHIKA PEAKDIGLIG HVVPDGQALE KALELANMIA GNGPLAVQAV LKTIRDSEGM HENEAFKADT KVGIGVFTSN DAKEGPRAFA EKRAPNFTGS

NT Sequence
TTGACCGAAG CTGACGCTCT TCGCGCAAGC GGCTCATCGC ACACCGTGAC CGAGCAGGAC GCCCCGCATG CTCTGGTGGA ACTCCGCGAT CACGTCCTCA TCGTGACGAT GAATCGTCCG CACGCACGCA ACGCCCTGTC CGGGGAAATG CTGGAGATCA TGACGCAGGC CTGGGACCGC GTCGACAATG ATCCGGAGGT CCGGGTCTGC ATCCTGACCG GTGCGGGCGG ATATTTCTGC GCCGGAGCCG ACCTCAAAGC CATGAACAAG CGCGCCCCAG GTGATCAATT CTCCGATGGC AGCTACGATC CCTCGGTCAT CCCCGGTCTA CTCAAGGGGC GCCGTCTGAC CAAACCGCTC ATCGCGGCCG TCGAAGGTCC CGCAATCGCC GGTGGCACCG AGATCCTGCA AGCCACCGAT ATCCGTGTCG CGGGTGAGAG CGCCAAATTC GGTGTCTCTG AGGTGAAGTG GAGCCTGTAC CCGATGGGCG GATCCGCGGT GCGGCTGCCC CGCCAGATCC CGTACACGGT CGCCTGCGAC ATCTTGTTGA CCGGCCGACA CATCAAGGCC CCGGAGGCCA AGGACATCGG ACTCATCGGA CATGTCGTTC CGGACGGTCA GGCCCTGGAG AAGGCGCTGG AACTGGCCAA TATGATCGCC GGCAACGGGC CTCTCGCGGT CCAGGCGGTC CTCAAGACCA TCCGCGATTC GGAAGGCATG CACGAGAACG AGGCCTTCAA AGCCGACACC AAGGTCGGTA TCGGAGTCTT CACCAGTAAC GACGCCAAGG AAGGCCCGCG CGCCTTCGCC GAGAAGCGCG CACCCAACTT CACCGGCAGC

© 2021 Seattle Children's Research Institute. All rights reserved.